Success Metrics

Active Trials
7(100%)

Phase Distribution

Ph phase_2
2
29%
Ph early_phase_1
3
43%
Ph not_applicable
2
29%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
3(42.9%)
Phase 2Efficacy & side effects
2(28.6%)
N/ANon-phased studies
2(28.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

7

all time

Status Distribution
Active(7)

Detailed Status

Recruiting6
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
7
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Early Phase 13 (42.9%)
Phase 22 (28.6%)
N/A2 (28.6%)

Trials by Status

active_not_recruiting114%
recruiting686%

Recent Activity

7 active trials
Showing 5 of 7
active_not_recruitingnot_applicable

[18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer

NCT06580015
recruitingphase_2

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

NCT07025369
recruitingearly_phase_1

Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial

NCT07164027
recruitingnot_applicable

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

NCT06389786
recruitingphase_2

An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique

NCT06865768
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06580015Not Applicable

[18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer

Active Not Recruiting
NCT07025369Phase 2

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

Recruiting
NCT07164027Early Phase 1

Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial

Recruiting
NCT06389786Not Applicable

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

Recruiting
NCT06865768Phase 2

An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique

Recruiting
NCT05852041Early Phase 1

rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance

Recruiting
NCT06813898Early Phase 1

An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial

Recruiting

All 7 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
7